CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
A211901 | Alliance | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions | Cancer Prevention and Control CIRB | Available to Open |
ANHL04B1 | COG | Rare and Cutaneous Non-Hodgkin Lymphoma Registry | Pediatric CIRB | Available to Open |
10561 | ETCTN | Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab | Adult CIRB - Early Phase Emphasis | Available to Open |
10490 | ETCTN | Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide | Adult CIRB - Early Phase Emphasis | Available to Open |
CALGB-30607 | CALGB | Randomized; Phase III; Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511; IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced; Stage IIIB/IV Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Completed |
E2810 | ECOG | Randomized; Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy | Adult CIRB - Late Phase Emphasis | Available to Open |
S1925 | SWOG | Randomized, Phase II Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study | Adult CIRB - Late Phase Emphasis | Available to Open |
A021602 | Alliance | Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) | Adult CIRB - Late Phase Emphasis | Available to Open |
MAY2015-05-01 | CP-CTNet_CLO-Mayo Clinic | Randomized, double-blind, placebo-controlled trial of Meriva® (curcuminoids) as a candidate chemoprevention agent for gastric carcinogenesis | Cancer Prevention and Control CIRB | Available to Open |
A021502 | Alliance | Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) | Adult CIRB - Late Phase Emphasis | Available to Open |